GlycoMimetics GLYC Stock
GlycoMimetics Price Chart
GlycoMimetics GLYC Financial and Trading Overview
| GlycoMimetics stock price | 0.26 USD |
| Previous Close | 0.27 USD |
| Open | 0.27 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.26 - 0.27 USD |
| 52 Week Range | 0.14 - 3.5 USD |
| Volume | 238.36K USD |
| Avg. Volume | 20.76M USD |
| Market Cap | 17.57M USD |
| Beta (5Y Monthly) | 1.842 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.59 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1 USD |
GLYC Valuation Measures
| Enterprise Value | 3.82M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.0255554 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1757.2336 |
| Price/Book (mrq) | 0.4561139 |
| Enterprise Value/Revenue | 381.762 |
| Enterprise Value/EBITDA | -0.094 |
Trading Information
GlycoMimetics Stock Price History
| Beta (5Y Monthly) | 1.842 |
| 52-Week Change | -91.56% |
| S&P500 52-Week Change | 23.80% |
| 52 Week High | 3.5 USD |
| 52 Week Low | 0.14 USD |
| 50-Day Moving Average | 0.29 USD |
| 200-Day Moving Average | 0.42 USD |
GLYC Share Statistics
| Avg. Volume (3 month) | 20.76M USD |
| Avg. Daily Volume (10-Days) | 175.61K USD |
| Shares Outstanding | 64.53M |
| Float | 42.53M |
| Short Ratio | 1.07 |
| % Held by Insiders | 3.12% |
| % Held by Institutions | 47.91% |
| Shares Short | 5.64M |
| Short % of Float | 12.60% |
| Short % of Shares Outstanding | 8.74% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2023 |
| Most Recent Quarter (mrq) | June 30, 2024 |
| Next Fiscal Year End | December 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -408770.50% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -59.24% |
| Return on Equity (ttm) | -104.49% |
Income Statement
| Revenue (ttm) | 10K USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 10K USD |
| EBITDA | -40783964 USD |
| Net Income Avi to Common (ttm) | -39113232 USD |
| Diluted EPS (ttm) | -0.62 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 22.39M USD |
| Total Cash Per Share (mrq) | 0.35 USD |
| Total Debt (mrq) | 448.78K USD |
| Total Debt/Equity (mrq) | 2.24 USD |
| Current Ratio (mrq) | 5.477 |
| Book Value Per Share (mrq) | 0.597 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -35700392 USD |
| Levered Free Cash Flow (ttm) | -22150632 USD |
Profile of GlycoMimetics
| Country | United States |
| State | MD |
| City | Rockville |
| Address | 9708 Medical Center Drive |
| ZIP | 20850 |
| Phone | 240 243 1201 |
| Website | https://www.glycomimetics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 35 |
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Q&A For GlycoMimetics Stock
What is a current GLYC stock price?
GlycoMimetics GLYC stock price today per share is 0.26 USD.
How to purchase GlycoMimetics stock?
You can buy GLYC shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GlycoMimetics?
The stock symbol or ticker of GlycoMimetics is GLYC.
Which industry does the GlycoMimetics company belong to?
The GlycoMimetics industry is Biotechnology.
How many shares does GlycoMimetics have in circulation?
The max supply of GlycoMimetics shares is 64.51M.
What is GlycoMimetics Price to Earnings Ratio (PE Ratio)?
GlycoMimetics PE Ratio is now.
What was GlycoMimetics earnings per share over the trailing 12 months (TTM)?
GlycoMimetics EPS is -0.59 USD over the trailing 12 months.
Which sector does the GlycoMimetics company belong to?
The GlycoMimetics sector is Healthcare.
GlycoMimetics GLYC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 21278.67 USD — |
+1.26
|
— — | 20945.45 USD — | 21305.05 USD — | — - | — — |
- {{ link.label }} {{link}}